L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 564.1 ILS -0.04% Market Closed
Market Cap: 446.1m ILS

Lineage Cell Therapeutics Inc
Interest Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lineage Cell Therapeutics Inc
Interest Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Expense CAGR 3Y CAGR 5Y CAGR 10Y
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Interest Expense
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Expense
$2.9B
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
16%
Gilead Sciences Inc
NASDAQ:GILD
Interest Expense
$1B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Interest Expense
$2.8B
CAGR 3-Years
29%
CAGR 5-Years
18%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Expense
$12.8m
CAGR 3-Years
-40%
CAGR 5-Years
-26%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Expense
$42.1m
CAGR 3-Years
-9%
CAGR 5-Years
-3%
CAGR 10-Years
10%
No Stocks Found

Lineage Cell Therapeutics Inc
Glance View

Market Cap
446.1m ILS
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

LCTX Intrinsic Value
512.21 ILS
Overvaluation 9%
Intrinsic Value
Price
L

See Also

Back to Top